Loperamide HCl 2 mg Oral Tablet
RxNorm 978010
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 978010 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: loperamide HCl 2 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Loperamide hydrochloride 2 mg Oral Tablet
(Atom ID: 12343786)
PSNPrescribable
Prescribable Name (PSN):
Loperamide HCl 2 mg Oral Tablet
(Atom ID: 6394255)
PTPrescribable
Designated preferred name (PT):
Loperamide hydrochloride 2 mg oral tablet
(Atom ID: 9251599)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely loperamide hydrochloride 2 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 10314379)
Patient Education
Loperamide
Nonprescription (over-the-counter) loperamide is used to control acute diarrhea (loose stools that come on suddenly and usually lasts less than 2 weeks), including travelers' diarrhea. Prescription loperamide is also used to control acute diarrhea and also ongoing diarrhea associated with inflammatory bowel disease (IBD; condition in which the lining of all or part of the intestine is swollen, irritated, or has sores). Prescription loperamide is also used to reduce the amount of fluid in people with ileostomies (surgery to create an opening for waste to leave the body through the abdomen). Loperamide is in a class of medications called antidiarrheal agents. It works by decreasing the flow of fluids and electrolytes into the bowel and by slowing down the movement of the bowel to decrease the number of bowel movements.
[Learn More]
* Please review the disclaimer below.